MedCity News November 2, 2021
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News.
Why did you join Pillar Biosciences?
I am incredibly impressed with the technology and the amazing team at Pillar that have done so much work to bring our oncoReveal™ Dx Lung and Colon Cancer Assay, a next generation sequencing (NGS), tissue-based companion diagnostic test to the market. Our FDA-approved product can be used by any lab that conducts NGS testing, making precision medicine...
Today's Sponsors
Today's Sponsor